We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Smartphones Could Diagnose Diseases Using Infrared Scans

By LabMedica International staff writers
Posted on 31 Mar 2025

Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor. More...

This innovative approach to personalized medicine and disease diagnostics is being driven by groundbreaking research at Georgia State University (Atlanta, GA, USA).

A research team at Georgia State University is pioneering non-invasive, accessible medical diagnostics through the use of ATR-FTIR spectroscopy, which stands for attenuated total reflectance-Fourier transform infrared spectroscopy. This technique allows for the examination of the molecular composition of materials by using infrared light to uncover minute details that are typically not visible. Applied to medical diagnostics, this technology enables the early detection of diseases like melanoma through an infrared scan. The research has already shown considerable promise in improving diagnostic capabilities for various conditions, earning patents for the detection of melanoma, lymphoma, colitis, and other forms of cell activation.

Currently, the team is focusing on tracking disease progression. Their latest research aims to measure how a disease develops over time, identifying key milestones that could eventually be used in clinical environments. This type of diagnostic technology could, for example, be used to assess the effectiveness of a specific treatment, allowing doctors to make timely adjustments. The main advantage of ATR-FTIR spectroscopy is its ability to provide precise molecular data and track disease progression without requiring invasive procedures. The researchers aim to embed this technology into everyday devices, enabling individuals to monitor their health from home, and eliminating the need to visit a clinic. According to scientists, these advancements can potentially revolutionize how we diagnose a wide range of illnesses, from common colds to colon cancer.

“In 10 to 15 years, I hope to see this technology in your smartphone, and in your everyday life,” said Regents’ Professor of Physics Unil Perera who is leading the team. “Imagine being able to take your own health readings from the comfort of your home. The potential for early detection and personalized medicine is enormous.”

Related Links:
Georgia State University


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.